A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SAPPHIRE
- Sponsors Mirati Therapeutics
Most Recent Events
- 28 Mar 2025 Planned End Date changed from 31 Dec 2024 to 23 Jun 2025.
- 25 Jun 2024 Planned End Date changed from 30 Apr 2024 to 31 Dec 2024.
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress